Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Repro/Endo flashcards > Endo Pharm > Flashcards

Endo Pharm Flashcards

1
Q

Metformin

A

MOA: Decreases hepatic glucose production

PK: rapidly absorbed in small intestine (no liver metabolism), excreted unchanged in urine. t1/2= 4-9 hours. Takes 2 weeks for maximal effect

Side effects: GI (30% patients, only 5% stopped meds); lactic acidosis (rare, high fatality rate); reduced vitamin B12 (30%, but rarely causes anemia)

Contraindications: renal disease (creatinine greater than 1.5), active liver disease (lactic acidosis risk), discontinue with iodinated contrast medium administration

Uses: Lowers A1C 1-2%; mild weight loss; prevents diabetes in pre-diabetics; favorable lipid effects (small); decreased CV disease, malignancies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q
  • Glipizide
  • Glyburide
  • Glimepiride
  • Tolbutamide
  • Chlorpropamide
A

Sulfonylureas

MOA: bind to sulfonylurea receptor to block K+ exit from beta-cell–> Ca+2 release–> insulin release

PK: Kidney exretion

Side effects: Hypoglycemia (most common), mild weight gain, dizziness, headache, nausea (rare)

Contraindications: Patients at risk of hypoglycemia; sulfonamide allergy (sulfa antibiotics)

Uses: lower A1C 1-2%; works quickly; long term failure in 30% patients; flat dose-response relationship (max response at 1/2 maximal dose); NO improvement in insulin resistance or CV risk factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Repaglinide

A

Meglitinides
Slightly different structure, receptor than sulfonylureas, but same MOA. Shorter half life

Advantages: less hypoglycemia than sulfonylureas (act quicker, degrade faster)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Rosiglitazon (Avandia)

A

Thiazolidinediones
MOA: increase insulin sensitivity by stimulating PPAR gamma:
- Promotes differentiation of small, metabolically active adipocytes
- Alters level of secretory products (reduces TNF and FFA)
- Raises adiponectin
- Alters adipose tissue distribution (shifts visceral fat to subcutaneous distribution)
Leads to improved insulin action, glucose metabolism, vascular function

  • Rosiglitazone associated with increased risk of ischmic cardiac events–> restricted use
  • Full clinical effect is slow (2-4 moths) due to alterations in adipocytes/fat distribution
  • Won’t cause hypoglycemia

PK: liver metabolism; biologic half life= hours, pharmacologic= months

Side effects: peripheral edema (4-6%); weight gain (2-3 kg over 1 year); osteoporosis; hepatotoxicity (rare); macular edema (rare)

Clinical use: lower A1c .5-1.4% (small glucose lower effects)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Acarbose

A

Alpha-glucosidase inhibitors

MOA: inhibit upper GI enzymes that convert complex polysaccharide carbs into monosaccharides (slow absorption of glucose, slower rise in postprandial blood glucose

Side effects: GI (GAS!)

Clinical use: only lowers A1C 0.5%, dosed 3 times/day, low hypoglycemia risk, RARELY USED due to weak glucose lowering effects plus bad side effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Exenatide

A

MOA: synthetic version of Gila monster salivary protein; binds to GLP-1 receptors on beta cells–> stimulates insulin secretion, inhibits glucagon, slows gastric emptying, causes early satiety

PK: minimal systemic metabolism; proteolytic degradation; exenatide t1/2= 2-4 hours, liraglutide 1/2= 13 hours

Side effects: Nausea (suppresses appetite), jittery/dizzy, headache, pancreatitis, renal failure (do not use with renal clearance < 30), c-cell tumors (contraindicated in medullary thyroid cancer/MEN-2)

Clinical use: decrease in A1c 0.5-1.2%, weight loss (5-10 lbs), exenatide dose with meals (liraglutide dosed 2 times/day)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Gliptins

A

MOA: DPP-4 Inhibitor= inhibit dipeptidyl peptidase-4, thus blocking breakdown of GLP-1/GIP

Side effects: nasopharyngitis, URI, headache, pancreatitis, hypersensitivity rxn

Clinical use: lower A1c 0.5%-0.9%, once daily, weight neutral, low hypoglycemia risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Pramlintide

A

MOA: analog of amylin inhibiting glucagon secretion, slows gastric emptying (delays absorption of carbs)

Side effects: nausea, hypoglycemia

Clinical use: insulin treated DM (sub-q injection before meals- lower insulin to prevent hypoglycemia), lowers A1c 0.5-0.6%, mild weight loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Colesevalam

A

MOA: bile acid sequestrant

Side effects: GI

Clinical use: lowers A1c 0.5%; needs to be taken as powder or 6 pills/day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Sermorelin

A

1st 29 aa of native GHRH

  • Clinical uses: diagnosis of pituitary dwarfism (in children of short stature): administration should increase GH in hypothalamic GHRH defect
  • Administered IV/SC; 12- minute half-life
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Hexarelin

A

6 aa native GHRH

  • Clinical uses: diagnosis of pituitary dwarfism (in children of short stature): administration should increase GH in hypothalamic GHRH defect
  • Administered intranasally
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Growth hormone: somatotropin/somatrem

A

Promotes growth of long bones, muscle growth (anabolic), lipolysis, increased plasma glucose by binding GH single-transmembrane receptors

  • Somatotropin= animal-derived bHG
  • Somatropin/somatrem= rDNA HGH

Clinical uses: replacement therapy for:

  • Attaining satisfactory height (until epiphyseal plate closure) in GH-deficiency dwarfism (<4cm/year)
  • Long-term treatment of adults with idiopathic short stature
  • Reverse catabolic states (AIDS, wasting)
  • Improved GI function in short bowel syndrome

Adverse effects: diabetes, hypothyroidism, carpal tunnel syndrome, swelling

Contraindications: Praeder-Willi syndrome (respiratory problems); active tumors/hx tumors; growth promotion in pts with closed epiphyseal plates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Mecasermin

A

Recombinant human IGF-1 and human insulin-like growth factor binding protein-3

Uses: children with growth factor, IGF-1 deficiency who are not responsive to GH (mutation in GH receptor, antibodies against GH)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Pegvisomant

A

Growth hormone receptor antagonist: PEG derivative of mutant GH with altered receptor-binding properties

Uses: second line therapy for treating acromegaly (after surgery)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Octreotide

A

Somatostatin analog: decreases GH release from anterior pituitary; inhibits release of gastrin, pepsin, glucagons, gastric acid

IM slow release (monthly)

Uses:

  • reduce GH in acromegaly patients
  • gastrinoma/glucagonoma and severe diarrhea (diabetic, secretory)

Adverse effects: GI, biliary, cardiac (bradycardia), glucose intolerance, B12 deficiency

Contraindications: hepatic, renal impairment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Lanreotide

A

Somatostatin analog: decreases GH release from anterior pituitary

Uses: indicated for acromegaly

Adverse effects: GI, biliary, cardiac (bradycardia), glucose intolerance, B12 deficiency

Contraindications: hepatic, renal impairment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Bromocriptine

A

Oral dopamine agonist:

  • Decrease release of prolactin
  • Lowers neurotransmitter activities that induce/maintaining glucose-resistant state of diabetes
  • Oral medication

Uses:

  • Treat hyperprolactinemia related to prolactinoma (galactorrhea, hypogonadism)
  • Inhibit post-partum lactation
  • DM: weak glucose-lowering effect (A1c 0.5%), decrease CV disease

Side efects: nausea, light-headedness, orthostatic hypotension, constipation

Contraindications: uncontrolled hypertension, ischemic heart disease, PVD, history of schizophrenia (dopaminergic)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Cabergoline

A

Oral dopamine agonist: decrease release of prolactin

  • longer half-life than bromocriptine, more effective binding, less nausea/GI side effects

Uses:

  • Treat hyperprolactinemia related to prolactinoma
  • Inhibit post-partum lactation

Side efects: nausea, light-headedness, orthostatic hypotension, constipation

Contraindications: uncontrolled hypertension, ischemic heart disease, PVD, history of schizophrenia (dopaminergic)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Aqueous Vasopressin

A

Synthetic vasopressin mimicking effects of ADH: increased water resorption

  • short-acting version: 3-6 hours
  • Administered IM, IV, SC
    Uses: transient diabetes insipidus

Side effects:

  • Nausea, HA, cramping
  • Hyponatremia
  • Vasopressor on coronary vessels in large doses–> angina

Contraindications: moderate to severe renal impairment, history of hyponatremia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Vasopressin tannate in oil

A

Synthetic vasopressin mimicking effects of ADH: increased water resorption

  • long-acting: 24-72 hours
  • IM administration

Uses: Diabetes insipidus, esophageal varocele bleeding, colonic diverticular bleeding

Side effects:

  • Nausea, HA, cramping
  • Hyponatremia
  • Vasopressor on coronary vessels in large doses–> angina

Contraindications: moderate to severe renal impairment, history of hyponatremia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Lysine vasopressin

A

Synthetic vasopressin mimicking effects of ADH: increased water resorption

  • short-acting: 4-6 hours
  • Nasal spray administration

Uses: Diabetes insipidus, esophageal varocele bleeding, colonic diverticular bleeding

Side effects:

  • Nausea, HA, cramping
  • Hyponatremia
  • Vasopressor on coronary vessels in large doses–> angina

Contraindications: moderate to severe renal impairment, history of hyponatremia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Desmopressin (DDAVP)

A

Synthetic vasopressin mimicking effects of ADH: increased water resorption

  • Oral medication

Uses: Diabetes insipidus, esophageal varocele bleeding, colonic diverticular bleeding, NO LONGER used forPrimary nocturnal enuresis (PNE)

Side effects:

  • Nausea, HA, cramping
  • Hyponatremia (Desmopressin= CONTRAINDICATION)
  • Vasopressor on coronary vessels in large doses–> angina

Contraindications: moderate to severe renal impairment, history of hyponatremia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Demeclocycline

A

Tetracycline used for SIADH (syndrome of inappropriate ADH secretion)

  • Oral administration
  • Antagonizes ADH on renal tubules
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Conivaptan

A

SIADH med: Vasopressin receptor antagonist used in euvolemic hyponatremia (blocks effects of ADH causing water retention)

  • CYP3A4 inhibitor
  • Adverse effects: hypokalemia, orthostatic hypotension, polyuria
  • Contraindications: hypovolemic hyponatremia, use with CYP3A4 inhibitor
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Oxytocin

A

Induces uterine contractions (alters ion currents across smooth muscle cell membranes), maintains labor, enhances cervical dilation, elicits milk ejection

Uses:

  • Induce, support labor in early vaginal delivery
  • Low dose: contraction of uterus (increase force, frequency)
  • High dose: prolonged contractions of uterus, decreases BP causing reflex tachycardia
  • Nasal spray: induce lactation post-partum
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Methylergonovine

A

Rapid, prolonged control of post-partum uterine hemorrhage

- Oral administration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Prostoglandins:

  • Gemeprost (PGE1)
  • Dinoprostone (PGE2)
  • Carboprost (PGF2alpha)
A

Administered injection, intra-amniotically or intravaginally

Uses:

  • Low dose= induces, reinforces labor
  • High dose= control post-partum bleeding, induce 1st/2nd trimester abortions

Adverse effects: diarrhea, hyperthermia, bronchoconstriction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Ritodrine

A

Beta-2 selective agonist: relaxes pregnant uterus to prevent/delay premature parturition

  • Oral administration
  • Adverse effects: skeletal muscle tremor, tachycardia
  • Contraindications: maternal cardiac disease, HTN (pregnancy-induced), uncontrolled DM, hyperthyroidism, hypovolemia, multiple gestation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Terbutaline

A

Beta-2 selective agonist: relaxes pregnant uterus to prevent/delay premature parturition

  • Oral administration
  • Adverse effects: skeletal muscle tremor, tachycardia
  • Contraindications: maternal cardiac disease, HTN (pregnancy-induced), uncontrolled DM, hyperthyroidism, hypovolemia, multiple gestation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Magnesium sulfate

A

Prevents/delays premature parturition (tocolytic)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Meds for acromegaly

A

Pegvisomant (GH receptor antagonist)

Octreotide (somatostatin analogue- inhibits GH release)

32
Q

Meds for dwarfism

A

Somatotropin (bGH)
Somatrem, somatropin (HGH)
Mecasermin (IGF-1 recombinant)

33
Q

Meds for prolactinemia

A

Bromocriptin, cabergoline (dopamine agonists)

34
Q

Diabetes insipidus meds

A

Central: Vasopressins
Nephrogenic: NSAIDs

35
Q

Stimulation of uterine contractions

A

Prostaglandins (gemeprost, dinoprostone, carboprost)

Oxytocin

36
Q

Inhibition of uterine contractions (tocolytics)

A

Terbutaline, ritodrine= beta-2 selective agonists

Magnesium sulfate

37
Q

Synthetic TH

A

Used in treatment of hypothyroidism

  • Synthetic T4 best absorbed in duodenum, ileum (80%)
  • Synthetic T3 has 95% absorbtion
  • Absorption decreased by food, iron, aluminum-containing antacids, sucralfate, calcium preparations
  • Metabolic clearance increased in drugs inducing liver metabolsim (rifampin, phenobarbital, carbamasepine, phenytoin)
38
Q

Levothyroxine

A

L-T4 supplement (drug of choice for hypothyroidism

Takes longer to activate than T3 supplements (longer to take effect, fewer side effects)

Brands: Synthroid, Levoxyl, Unithroid, Levothroid

39
Q

Liothyronine

A

T3 supplement: cytomel

40
Q

Liothrix

A

T4/T3 supplement:

Thyrolar

41
Q

Dessicated thyroid

A

Armour thyroid: combination of types of thyroid (“complete replacement”- not recommended)

42
Q

Methimazole (MMI)

A

Thionamide: inhibit TPO, block iodine organification. Do NOT block iodide uptake by gland
More potent than Propylthioruacyl (PTU)
- Readily crosses placenta

Dose: 1 time a day

Used in treatment of hyperthyroidism; preferred treatment in MOST cases of hyperthyroidism

Side effects:

  • 3-12% patients: maculopapular rash, GI
  • Rare: vasculitis, arthralgia, lupus, liver issues, lymphadenopathy
  • DANGER: agranulocytosis= neutrophil count < 500 mL (infrequent but fatal- can’t fight off infections)
43
Q

Propylothiouracyl (PTU)

A

Thionamide: inhibit TPO, block iodine organification. *Inhibits conversion of T4 to T3 (unlike methimazole). Do NOT block iodide uptake by gland

  • Less potent than methimazole*
  • Given in first trimester pregnancy to avoid harm to fetus (see what happens)

Dose: 3 times a day

Used in treatment of hyperthyroidism: preferred treatment in pregnancy and Thyroid storm (toxic state) to lower T4-T3 conversion (prevents metabolic conversion)

Side effects:

  • 3-12% patients: maculopapular rash, GI
  • Rare: vasculitis, arthralgia, lupus, liver issues, lymphadenopathy
  • DANGER: agranulocytosis= neutrophil count < 500 mL (infrequent but fatal- can’t fight off infections)
44
Q

Iodides

A

Pharmacologic dose inhibits release of TH (inhibits TBG proteolysis?).

  • Rapidly improves thyrotoxic storm (2-7 days).
  • Decreases vascularity, size, fragility of hyperplastic gland for pre-operative preparation

Side effects: skin rash

Dosing: potassium iodide solution

45
Q

Iodinated contrast media

A

Inhibit conversion of T4 to T3; inhibits release of thyroid hormone

Uses: thyroid storm treatment

Adverse effects: rare allergic reaction to contrast media

46
Q

Radioactive iodine

A

I-131= treatment of thyrotoxicosis; destroys thyroid parenchyma–> can lead to HYPOthyroidism
- readily incorporated into thyroid follicles

Safe: no genetic damage, no leukemia, no neoplasia (v. low dose)

Caution: avoid in pregnancy or nursing (can kill fetal/infant thyroid)

47
Q

Beta-blockers for thyroid

A

Given to treat SYMPTOMS of hyperthyroidism:

  • Palpitations
  • Anxiety
48
Q

Caclium supplementation: adverse reactions

A 
Major:
- Constipation
- Nausea
- Abdominal pain
- Milk alkali syndrome (hypercalcemia, metabolic alkalosis, renal insufficiency)
Hypophosphatemia
49
Q

Calcium supplementation: Drug/food interactions

A
  • Calcium channel blockers
  • LEVOTHYROXINE
  • Antibiotics, atenolol, rion
  • Thiazide diuretics
  • Potentiate digoxin toxicity
50
Q

Pharmacokinetics of calcium supplementation

A
  • Calcium carbonate absorption better taken with meals (ACIDIC environment)
  • Calcium citrate absorbed in fasting state (best in older patients, patients with achlorhydria)
51
Q

Indications for IV calcium

A

Symptomatic hypocalcemia (serum calcium < 7mg/dL)

  • Paresthesias
  • Tetany
  • Hypotension
  • Seizures
  • Chvostek’s
  • Trousseau’s
  • Bradycardia
  • Prolongation of QT interval
52
Q

Bisphosphanates: MOA

A
  • Inhibit osteoclast bone resorption: attach to bone surfaces undergoing active resorption–> impair ruffled border formation in osteoclast
  • Decrease osteoclast cell number
  • Increase BMD, decrease fracture risk
53
Q

Bisphosphanates: PK

A

Poorly absorbed from GI tract: best on empty stomach

- t1/2= up to 10 years

54
Q

Bisphosphanates: Adverse effects/ contraindications

A
  • GI (abdominal pain, esophageal erosions)
  • Hypocalcemia (Vit D or Ca deficiency increases risk)
  • Ocular
  • Musculoskeletal pain
  • Osteonecrosis of jaw

Contraindications: hypocalcemia, abnormalities of esophagus

55
Q

Clinical use of Bisphosphanates

A

Oral: Alendronate, risedronate= treat osteoporosis, decrease fracture rates

IV: Zoledronic acid= treats hypercalcemia of malignancy, osteoporosis (once yearly infusion), decrease fractures
* Monitor creatinine (renal function) prior to each dose

56
Q

Calcitonin

A

Produced by parafollicular cells surrounding thyroid follicle cells- inhibits osteoclasts, stimulates osteoblasts, increases calcium and phosphate excretion

Preparations: Salmon-derived injectable (severe hypercalcemia tx) or inhaled (no effect on calcium- very weak effects on BMD, slight reductions in fractures)

57
Q

Estrogen therapy for Osteoporosis

A

NOT recommended first-line agent (due to increased risks of CV events)

58
Q

Raloxifine

A

Selective Estrogen Receptor Modulator (SERM)

  • Reduces risk of spine fractures- more preventive than therapeutic for fracture patients
  • Can increase risk of DVT
59
Q

Teraparatide

A

MOA: PTH–> stimulates osteoblasts, reabsorption of calcium

Paradox: PULSATILE PTH= anabolic, stimulates osteoblasts (vs constant PTH= osteoclast activity increased)

Uses: most effective osteoporosis treatment

Dosing/adminstration= subcutaneous injection
Candidates:
- Severe osteoporosis (-3.5 or less)
- Osteoporosis (-2.5 or less) + fragility fracture
- Failure of oral bisphosphanates

Adverse reactions: usually due to injection, can’t use for >2 years due to osteosarcoma risk

60
Q

Denosumab

A

Human monoclonal antibody binds to RANK-L

MOA: Blocks/interferes with TNF ligand that binds to receptors on pre-osteoclasts–> maturation of osteoclast (Blocks osteoclast maturation, thus bone resorption)

  • Adverse effects: musculoskeletal pain, eczema, cellulitis, hypocalcemia
    • Slight increase in risk of infection due to RANK-L effects on immune function

Dosing: subcutaneous injection every 6 months

61
Q

Calcimimetics

A
  • Allosterically increases sensitivity of CaSR in parathyroid gland to calcium
  • use in dialysis population
  • hyperparathyroidism without possible surgery
62
Q

Vitamin D supplementation

A

MOA: 1,25-OH D binds to DNA in intestinal mucosa, bone, kidney tubule cells–> increases intestinal calcium, phosphate absorption

  • Amplifies action of PTH on bone
  • Inhibits PTH transcription in chief cells in parathyroid gland

PK: easier to absorb than calcium. taken as ergocalciferol (D2) or cholecalciferol (D3- may increase serum 25OH D better than ergo)

Adverse reactions: intoxication–> symptoms of hypercalcemia

  • Assess Vit D status by measuring 25OH-D
63
Q

Calcitriol

A

Synthetic vitamin D: regulates Ca absorption from GI tract

Uses: most active form of VitD to stimulate Ca absorption–> indicated for hypocalcemia, hypoparathyroidism-induced hypocalcemia

64
Q

Glucocorticoids: indications

A

Endocrine use: diagnosis and cause of Cushing’s syndrome; treat adrenal insufficiency, congenital adrenal hyperplasia

Non-endocrine use: autoimmune disease, allergies, organ transplant, cancers, derm diseases, respiratory diseases, ophthalmic conditions, GI, nervous system (MS)

  • All topical, inhaled glucocorticoids absorbed to some extent- can also cause disturbances in hypo-pit-adrenal axis (suppression, Cushing’s)
  • intertriginous areas» forehead > scalp > face > forearm
65
Q

Glucocorticoids: AE

A
  1. Suppression of Hyp-pit-ad axis
    - Likely: > 20 mg prednisone/day for > 3 weeks; bedtime evening dose for > 3 weeks; “Cushingoid appearance”
    - Unlikely: < 3 weeks (any dose); alternate day dosing
  • avoid adrenal suppression by tapering doses (huge loading dose, taper off) or alternate day administration
    2. Cushing’s
  1. Other:
    - Fat shifts
    - hyperglycemia (diabetes)
    - Osteoporosis
    - Muscle wasting
    - Psychosis
    - Electrolyte imbalance–> edema
66
Q

Mineralocorticoids

A

Aldosterone (+ progesterone, deoxycorticosterone)–> sodium retention
- Aldosterone upregulates Na and K channels: dumps K, resorbs Na

67
Q

Fludrocortisone

A

Replacement therapy in primary adrenocortical insufficiency

MOA: acts like aldosterone (on distal tubules)

AEs: hypokalemia, HTN (increased electrolytes), edema

Monitoring: orthostatic hypotension measurements, pulse, edema, serum K, plasma renin

68
Q

DHEA-S

A 
Adrenal androgen (converted from DHEA)
- Can be used as androgen replacement therapy in WOMEN to help with libido (doesn't really help in men)
69
Q

Mitotane

A

Adrenocorticolytic drug for ADRENAL CARCINOMA
- medical adrenalectomy

AE: N/V, anorexia, diarrhea, rash, gynecomastia, ataxia, arthralgias, leukopenia, hypercholesterolemia, hepatotoxicity

70
Q

Ketoconazole

A

Most common agent used in treatment of Cushing’s disease (pituitary, ectopic)

  • Given much higher doses than for fungal infections
  • Inhibits first step in cortisol biosynthesis and blocks conversion of 11-deoxycortisol to cortisol
  • Inhibits ACTH by impairing corticotroph adenylate cyclase activation

AEs: headache, sedation, N/V, gynecomastia, decreased libido/impotence (inhibit testosterone), hepatotoxicity

  • monitor urine cortisol to adjust doses
71
Q

Spironolactone

A

Aldosterone receptor antagonist for non-surgical patients
- Progesterone and androgen receptor antagonist–> breast tenderness/menstrual irregularities, impotence, decreased libido, gynecomastoa

72
Q

Eplerenone

A

Mineralocorticoid receptor antagonist (selective)

  • Doesn’t bind androgen/progesterone receptors like spironolactone (fewer AEs)
  • More expensive
73
Q

Miglitol

A

Alpha-glucosidase inhibitors

MOA: inhibit upper GI enzymes that convert complex polysaccharide carbs into monosaccharides (slow absorption of glucose, slower rise in postprandial blood glucose

Side effects: GI (GAS!)

Clinical use: only lowers A1C 0.5%, dosed 3 times/day, low hypoglycemia risk, RARELY USED due to weak glucose lowering effects plus bad side effects

74
Q

Pioglitazone (Actos)

A

Thiazolidinediones
MOA: increase insulin sensitivity by stimulating PPAR gamma:
- Promotes differentiation of small, metabolically active adipocytes
- Alters level of secretory products (reduces TNF and FFA)
- Raises adiponectin
- Alters adipose tissue distribution (shifts visceral fat to subcutaneous distribution)
Leads to improved insulin action, glucose metabolism, vascular function

  • Rosiglitazone associated with increased risk of ischmic cardiac events–> restricted use
  • Full clinical effect is slow (2-4 moths) due to alterations in adipocytes/fat distribution
  • Won’t cause hypoglycemia

PK: liver metabolism; biologic half life= hours, pharmacologic= months

Side effects: peripheral edema (4-6%); weight gain (2-3 kg over 1 year); osteoporosis; hepatotoxicity (rare); macular edema (rare)

Clinical use: lower A1c .5-1.4% (small glucose lower effects)

75
Q

Nateglinide

A

Meglitinides

Slightly different structure, receptor than sulfonylureas, but same MOA. Shorter half life

76
Q

Liraglutide

A

MOA: synthetic version of Gila monster salivary protein; binds to GLP-1 receptors on beta cells–> stimulates insulin secretion, inhibits glucagon, slows gastric emptying, causes early satiety

PK: minimal systemic metabolism; proteolytic degradation; exenatide t1/2= 2-4 hours, liraglutide 1/2= 13 hours

Side effects: Nausea (suppresses appetite), jittery/dizzy, headache, pancreatitis, renal failure (do not use with renal clearance < 30), c-cell tumors (contraindicated in medullary thyroid cancer/MEN-2)

Clinical use: decrease in A1c 0.5-1.2%, weight loss (5-10 lbs), exenatide dose with meals (liraglutide dosed 2 times/day)

Repro/Endo flashcards (6 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions